Unlike ER-positive and Her2-positive breast tumors, which are candidates for endocrine and trastuzumab therapy, respectively, no targeted therapies for triple-negative breast tumors (TN; those lacking ER, PR, and Her2 overexpression) currently exist, making these a priority of translational research efforts. Here, ESR1 is linked to breast neoplasm.